Answer
Clarithromycin inhibits hepatic uptake and efflux transporters and may increase exposure to dalbavancin, although whether dalbavancin is a substrate for these transporters is unknown and clinical drug-interaction studies have not been conducted.
Sources for this answer
- Xydalba 500 mg powder for concentrate for solution for infusionADVANZ Pharma · emc · SmPC §4.5 Interaction with other medicinal products · Version 8Document updated
Sources checked